<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548048" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548048/" /><meta name="ncbi_pagename" content="Tizanidine - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Tizanidine - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Tizanidine" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2017/01/30" /><meta name="citation_pmid" content="31643379" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548048/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Tizanidine" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2017/01/30" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548048/" /><meta name="description" content="Tizanidine is a commonly used muscle relaxant that has been linked to rare instances of acute liver injury, a few of which have been fatal." /><meta name="og:title" content="Tizanidine" /><meta name="og:type" content="book" /><meta name="og:description" content="Tizanidine is a commonly used muscle relaxant that has been linked to rare instances of acute liver injury, a few of which have been fatal." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548048/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Tizanidine/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548048/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A79CB0467CBE10000000005230182.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548048_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548048_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Tipranavir/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Tobramycin/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548048_"><span class="title" itemprop="name">Tizanidine</span></h1><p class="small">Last Update: <span itemprop="dateModified">January 30, 2017</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Tizanidine.OVERVIEW"><h2 id="_Tizanidine_OVERVIEW_">OVERVIEW</h2><div id="Tizanidine.Introduction"><h3>Introduction</h3><p>Tizanidine is a commonly used muscle relaxant that has been linked to rare instances of acute liver injury, a few of which have been fatal.</p></div><div id="Tizanidine.Background"><h3>Background</h3><p>Tizanidine (tye zan' i deen) is an imidazoline derivative and is a centrally acting muscle relaxant used for therapy of acute muscle spasms and chronic spasticity. The mechanism by which tizanidine causes skeletal muscle relaxation is not well known; it appears to act at the level of spinal cord pain reflexes, most likely through activity as a central alpha-adrenergic agonist which results in an decrease in activity of motor neurons. Tizanidine was approved for use in the United States in 1996 and currently several million prescriptions are filled yearly. The current indications are limited to short-term management of spasticity. Tizanidine is available in several generic forms as well as under the brand name of Zanaflex in tablets and capsules of 2, 4 or 6 mg. The recommended dose in adults is 2 to 6 mg orally three to four times daily. Common side effects include tiredness, drowsiness, dizziness, muscular weakness, dry mouth and occasionally hypotension.</p></div><div id="Tizanidine.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Transient and asymptomatic elevations in serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> greater than 3 times the upper limit of normal occur in ~5% of patients taking tizanidine compared to 0.4% of subjects on placebo. Reports of severe hepatotoxicity, acute liver failure and death have been mentioned in review articles on tizanidine, but few case reports have been published. In these reports, the latency to onset of jaundice has ranged from 2 to 14 weeks and the enzyme elevations have been both cholestatic and hepatocellular (Case 1). Immunoallergic and autoimmune features have not been mentioned. Recovery was complete after 1 to 2 months.</p><p>Likelihood score: C (Probable rare cause of clinically apparent liver injury).</p></div><div id="Tizanidine.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of acute hepatic injury from tizanidine is unknown, but is probably idiosyncratic due to hypersensitivity.</p></div><div id="Tizanidine.Outcome_and_Management"><h3>Outcome and Management</h3><p>The idiosyncratic liver injury due to tizanidine ranges from hepatitis with jaundice to acute liver failure leading to death. Chronic injury and vanishing bile duct syndrome have not been reported after tizanidine therapy. Recurrence on re-exposure has been reported and rechallenge should be avoided. No cross reactivity with other muscle relaxants has been identified.</p><p>Drug Class: <a href="/books/n/livertox/MuscleRelaxants/">Muscle Relaxants</a></p></div></div><div id="Tizanidine.CASE_REPORT"><h2 id="_Tizanidine_CASE_REPORT_">CASE REPORT</h2><div id="Tizanidine.Case_1._Acute_hepatocellular_"><h3>Case 1. Acute hepatocellular injury with jaundice after tizanidine therapy.</h3><p>[Modified from: de Graaf EM, Oosterveld M, Tjabbes T, Stricker BH. A case of tizanidine-induced hepatic injury. J Hepatol 1996; 25: 772-3. <a href="https://www.ncbi.nlm.nih.gov/pubmed/8938559" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 55 year old woman with multiple sclerosis and lower limb muscle spasms developed jaundice 4 months after starting tizanidine therapy. The jaundice had been preceded by a 2 week period of progressive fatigue, nausea and poor appetite. She denied a history of liver disease or exposure to hepatitis and did not drink alcohol. Her other medications included baclofen, chlormezanone, diazepam, flurazepam, dexchlorpheniramine and diclofenac, all of which she had been taking chronically. On examination, she was deeply jaundiced and somnolent. She had no signs of chronic liver disease and did not have rash or fever. Laboratory testing showed a total bilirubin of 26.5 mg/dL and marked elevations in serum aminotransferase levels with minimal increase in alkaline phosphatase (Table). Tests for hepatitis A, B and C were negative as were autoantibodies (smooth muscle antibody was marginally positive). An abdominal ultrasound showed no evidence of biliary obstruction. Tizanidine had been discontinued 2 weeks before admission, but she worsened during the next several weeks, but then began a spontaneous recovery which was complete 2 months later. Several months later, the patient was inadvertently rechallenged with a single 4 mg dose of tizanidine and within 6 days the <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> levels had increased from 14 to 155 U/L. Tizanidine was discontinued again, and one week later serum ALT levels had returned to normal.</p><div id="Tizanidine.Key_Points"><h4>Key Points</h4><div id="Tizanidine.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548048/table/Tizanidine.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Tizanidine.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Tizanidine 36 mg daily</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular (R=15)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Severity:</td><td rowspan="1" colspan="1" style="vertical-align:top;">4+ (jaundice, hospitalization, mild hepatic failure)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</td><td rowspan="1" colspan="1" style="vertical-align:top;">14 weeks to onset of symptoms</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Complete recovery 2 months after stopping</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Baclofen, diclofenac, chlormezanone, diazepam, flurazepam, dexchlorpheniramine</td></tr></tbody></table></div></div></div><div id="Tizanidine.Laboratory_Values"><h4>Laboratory Values</h4><div id="Tizanidine.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548048/table/Tizanidine.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Tizanidine.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Tizanidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Tizanidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Tizanidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (U/L)</th><th id="hd_h_Tizanidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Tizanidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a>* (mg/dL)</th><th id="hd_h_Tizanidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Tizanidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Tizanidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Tizanidine.T2_1_1_1_3 hd_h_Tizanidine.T2_1_1_1_4 hd_h_Tizanidine.T2_1_1_1_5 hd_h_Tizanidine.T2_1_1_1_6" colspan="4" rowspan="1" style="vertical-align:top;">Tizanidine started</td></tr><tr><td headers="hd_h_Tizanidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">2 days</td><td headers="hd_h_Tizanidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Tizanidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Tizanidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Tizanidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Tizanidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Tizanidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">16 days</td><td headers="hd_h_Tizanidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Tizanidine.T2_1_1_1_3 hd_h_Tizanidine.T2_1_1_1_4 hd_h_Tizanidine.T2_1_1_1_5 hd_h_Tizanidine.T2_1_1_1_6" colspan="4" rowspan="1" style="vertical-align:top;">Tizanidine stopped</td></tr><tr><td headers="hd_h_Tizanidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">18 days</td><td headers="hd_h_Tizanidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 days</td><td headers="hd_h_Tizanidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">830</td><td headers="hd_h_Tizanidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">187</td><td headers="hd_h_Tizanidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">26.5</td><td headers="hd_h_Tizanidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Admission. INR=1.6</td></tr><tr><td headers="hd_h_Tizanidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">22 days</td><td headers="hd_h_Tizanidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">8 days</td><td headers="hd_h_Tizanidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">270</td><td headers="hd_h_Tizanidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Tizanidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">36.0</td><td headers="hd_h_Tizanidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Tizanidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">24 days</td><td headers="hd_h_Tizanidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">10 days</td><td headers="hd_h_Tizanidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">60</td><td headers="hd_h_Tizanidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Tizanidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">30.0</td><td headers="hd_h_Tizanidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Tizanidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">26 days</td><td headers="hd_h_Tizanidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">12 days</td><td headers="hd_h_Tizanidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">30</td><td headers="hd_h_Tizanidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Tizanidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">4.0</td><td headers="hd_h_Tizanidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Tizanidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">30 days</td><td headers="hd_h_Tizanidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">16 days</td><td headers="hd_h_Tizanidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">14</td><td headers="hd_h_Tizanidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Tizanidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.0</td><td headers="hd_h_Tizanidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Single dose of tizanidine</td></tr><tr><td headers="hd_h_Tizanidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">31 (1)** days</td><td headers="hd_h_Tizanidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">17 (1) days</td><td headers="hd_h_Tizanidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">155</td><td headers="hd_h_Tizanidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Tizanidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.0</td><td headers="hd_h_Tizanidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Tizanidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">32 (2) days</td><td headers="hd_h_Tizanidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">18 (2) days</td><td headers="hd_h_Tizanidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">30</td><td headers="hd_h_Tizanidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Tizanidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.0</td><td headers="hd_h_Tizanidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Tizanidine.T2_1_1_1_1 hd_h_Tizanidine.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Tizanidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;30</b></td><td headers="hd_h_Tizanidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;100</b></td><td headers="hd_h_Tizanidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Tizanidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div><p>* <a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> levels converted from &#x003bc;mol/L. Some values were estimated from Figure 1.</p><p>** Values in parentheses are the number of days after rechallenge</p></div><div id="Tizanidine.Comment"><h4>Comment</h4><p>The onset of hepatic injury after 4 months of therapy, the improvement with stopping treatment, and the accelerated recurrence of hepatic injury with restarting tizanidine make it highly likely that the hepatitis was due to tizanidine induced liver injury. The pattern of injury was distinctly hepatocellular. Diclofenac can also cause similar hepatocellular injury, but the other features and particularly the rechallenge argue in support of tinazidine as the cause. The rapidity of recurrence on reexposure suggests that the hepatic injury was due to hypersensitivity. The muscle relaxants are a diverse group of medications and share little in structure or mechanisms of action, so that cross sensitivity to hepatic injury should not be a problem. This patient was restarted on baclofen and a benzodiazepam without complication.</p></div></div></div><div id="Tizanidine.PRODUCT_INFORMATION"><h2 id="_Tizanidine_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Tizanidine.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Tizanidine &#x02013; Generic, Zanaflex&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Autonomic Agents: Muscle Relaxants, Central</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=tizanidine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product Labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Tizanidine.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Tizanidine_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Tizanidine.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548048/table/Tizanidine.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Tizanidine.T3_lrgtbl__"><table><thead><tr><th id="hd_h_Tizanidine.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Tizanidine.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NO</th><th id="hd_h_Tizanidine.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Tizanidine.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Tizanidine.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Tizanidine</td><td headers="hd_h_Tizanidine.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135001434" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">51322-75-9</a></td><td headers="hd_h_Tizanidine.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C9-H8-Cl-N5-S</td><td headers="hd_h_Tizanidine.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548048/bin/Tizanidine_Structure.jpg" alt="Tizanidine chemical structure" /></div></td></tr></tbody></table></div></div></div><div id="Tizanidine.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Tizanidine_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: January 30, 2017</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Tizanidine.R1">Zimmerman HJ. Muscle spasmolytics. In, Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd Ed. Philadelphia: Lippincott, 1999. p. 544-45.<div><i> (Expert review of hepatotoxicity published in 1999; discusses dantrolene, chlorzoxazone and baclofen, but not tizanidine).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R2">Hibbs RE, Zambon AC. Agents acting at the neuromuscular junction and autonomic ganglia. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s The pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill, 2011. p. 255-76. (Textbook of pharmacology and therapeutics).</div></li><li><div class="bk_ref" id="Tizanidine.R3">Fryda-Kaurimsky Z, M&#x000fc;ller-Fassbender H. Tizanidine (DS 103-282) in the treatment of acute paravertebral muscle spasm: a controlled trial comparing tizanidine and diazepam. J Int Med Res 1981; 9: 501-5.  [<a href="/pubmed/6459256" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6459256</span></a>]<div><i>(Among 10 patients treated with tizanidine, no mention of hepatic adverse effects).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R4">Smolenski C, Muff S, Smolenski-Kautz S. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 1981; 7: 374-83.  [<a href="/pubmed/7016449" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7016449</span></a>]<div><i>(Among 21 patients treated with tizanidine or baclofen for 6 weeks, no mention of hepatotoxicity of either drug).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R5">Newman PM, Nogues M, Newman PK, Weightman D, Hudgson P. Tizanidine in the treatment of spasticity. Eur J Clin Pharmacol 1982; 23: 31-5.  [<a href="/pubmed/6751834" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6751834</span></a>]<div><i>(Among 36 patients treated with tizanidine for chronic spasticity, 3 developed mild ALT elevations, but levels were below 50 U/L and resolved spontaneously).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R6">Lapierre Y, Bouchard S, Tansey C, Gendron D, Barkas WJ, Francis GS. Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci 1987; 14 (3 Suppl): 513-7.  [<a href="/pubmed/3676923" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3676923</span></a>]<div><i>(Among 33 patients treated with tizanidine, 2 developed significant ALT and AST elevations, both resolved after stopping drug).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R7">Stien R, Nordal HJ, Oftedal SI, Sletteb&#x000f8; M. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurol Scand 1987; 75: 190-4.  [<a href="/pubmed/3554879" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3554879</span></a>]<div><i>(Among 40 patients given either tizanidine or baclofen for 6 weeks, no changes observed in laboratory tests of liver function or mention made of hepatotoxicity of either drug).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R8">Bass B, Weinshenker B, Rice GP, Noseworthy JH, Cameron MGP, Hader W, Bouchard S, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988; 15: 15-9.  [<a href="/pubmed/3345456" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3345456</span></a>]<div><i>(Double blind cross over study of tizanidine vs baclofen for 5 weeks each; routine laboratory monitoring found no alterations in biochemical test results with either agent).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R9">Berry H, Hutchinson DR. A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. J Int Med Res 1988; 16: 75-82.  [<a href="/pubmed/2967780" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2967780</span></a>]<div><i>(Among 112 patients in a placebo controlled trial [59 treated with tizanidine], no hepatic adverse events reported).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R10">Berry H, Hutchinson DR. Tizanidine and ibuprofen in acute low-back pain: results of a double-blind multicentre study in general practice. J Int Med Res 1988; 16: 83-91.  [<a href="/pubmed/2967781" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2967781</span></a>]<div><i>(Placebo controlled trial of tizanidine with ibuprofen for 7 days in patients with low back pain; no hepatic adverse events reported in 51 tizanidine treated patients).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R11">Bes A, Eyssette M, Pierrot-Deseilligny E, Rohmer F, Warter JM. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin 1988; 10: 709-18.  [<a href="/pubmed/3286129" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3286129</span></a>]<div><i>(Randomized controlled trial of tizanidine versus diazepam for 8 weeks in 105 patients with spasticity; there were no changes in &#x0201c;biochemical parameters&#x0201d; during the study).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R12">Eyssette M, Rohmer F, Serratrice G, Warter JM, Boisson D. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin 1988; 10: 699-708.  [<a href="/pubmed/3286128" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3286128</span></a>]<div><i>(Among 100 patients in a randomized controlled trial of baclofen vs tizanidine for spasticity, 1 on tizanidine developed bilirubin and ALT elevations and skin rash, but ALT levels had been elevated before therapy).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R13">Hoogstraten MC, van der Ploeg RJ, vd Burg W, Vreeling A, van Marle S, Minderhoud JM. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta Neurol Scand 1988; 77: 224-30.  [<a href="/pubmed/3376747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3376747</span></a>]<div><i>(Among 16 patients treated with tizanidine and baclofen in a cross over study, muscle weakness was more common with baclofen; no mention of laboratory tests or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R14">Lang AE, Riley DE. Tizanidine in cranial dystonia. Clin Neuropharmacol 1992; 15: 142-7.  [<a href="/pubmed/1591739" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1591739</span></a>]<div><i>(Among 10 patients treated with tizanidine, one had elevated ALT levels before therapy which remained elevated during and after treatment).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R15">Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 1994; 44 (Suppl 9): S60-8; discussion S68-9.  [<a href="/pubmed/7970013" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7970013</span></a>]<div><i>(Review of 525 patients treated with tizanidine in 3 controlled trials, 2 patients developed significant liver enzyme elevations; but many had "slight" abnormalities [all &#x0003c;10 times ULN], which resolved with reduction of dosage or discontinuation).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R16">Rustemovic N, Huic M, Opacic M. Tinanidine-induced acute toxic hepatitis: case report. Pharmaca 1994; 32: 457-61. Not in PubMed.<div><i>(Report of toxic hepatitis cited in Henney [2009]).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R17">de Graaf EM, Oosterveld M, Tjabbes T, Stricker BH. A case of tizanidine-induced hepatic injury. J Hepatol 1996; 25: 772-3.  [<a href="/pubmed/8938559" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8938559</span></a>]<div><i>(55 year old woman developed jaundice 14 weeks after starting tizanidine [bilirubin 26.5 mg/dL, ALT 830 U/L, Alk P 187 U/L], resovling within 6 weeks; recurrence of ALT elevations after reexposure to a single tablet: Case 1).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R18">Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther 1998; 15: 241-51.  [<a href="/pubmed/10186943" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10186943</span></a>]<div><i>(In a metaanalysis of 10 trials in 270 patients comparing baclofen and tizanidine, both agents were said to be generally well tolerated; but, no mention was made of ALT abnormalities or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R19">Afonso P&#x000e9;rez E, Pego Reigosa R, Lancho Seco A, Bra&#x000f1;as Fern&#x000e1;ndez F. [Tizanidine-induced toxic hepatitis] Med Clin(Barc) 1999; 112: 478-9. Spanish.  [<a href="/pubmed/10320966" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10320966</span></a>]<div><i>(73 year old man received tizanidine for spasticity after ischemic stroke, developed malaise and jaundice 17 days later [bilirubin 7.2 mg/dL, ALT 616 U/L, Alk P 2810 U/L], resolving within 3 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R20">Saper JR, Winner PK, Lake AE 3rd. An open-label dose-titration study of the efficacy and tolerability of tizanidine hydrochloride tablets in the prophylaxis of chronic daily headache. Headache 2001; 41: 357-68.  [<a href="/pubmed/11318882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11318882</span></a>]<div><i>(Among 39 patients with frequent headaches treated for 12 weeks with tizanidine, one developed elevated ALT levels [320 U/L] without jaundice or symptoms, which resolved on stopping the drug).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R21">Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004; 28: 140-75.  [<a href="/pubmed/15276195" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15276195</span></a>]<div><i>(Thorough review of the pharmacology, efficacy and side effects of the muscle relaxants).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R22">Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug-induced liver injury in the United States. Liver Transpl 2004; 10: 1018-23.  [<a href="/pubmed/15390328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15390328</span></a>]<div><i>(Among ~50,000 liver transplants done in the US between 1990 and 2002, 270 [0.5%] were done for drug induced acute liver failure, but none were attributed to tizanidine or other muscle relaxants).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R23">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, one was attributed to chlorzoxazone, but none to tizanidine or other muscle relaxants).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R24">Henney HR 3rd, Chez M. Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment. Paediatr Drugs 2009;11:397-406.  [<a href="/pubmed/19877725" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19877725</span></a>]<div><i>(Summary of tizanidine adverse events in children from off-label use with major focus on somnolence, enuresis and anxiety; ALT elevations mentioned, but they were mild and largely attributed to concurrent anticonvulsant therapy).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R25">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76. <strong> <a href="https://www.ncbi.nlm.nih.gov/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>
</strong>. [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none were due to tizanidine or other muscle relaxants).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R26">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver iInjury in the General population of Iceland. Gastroenterology 2013; 144: 1419-25.  [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were attributed to tizanidine or other muscle relaxants).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R27">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann Hepatol 2014; 13: 231-9.  [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i> (Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases; one case was attributed to verapamil, but none were linked to amlodipine or other calcium channel blockers).</i></div></div></li><li><div class="bk_ref" id="Tizanidine.R28">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-1352.e7.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 5 [0.7%] were attributed to muscle relaxants, including one to trizanidine: 51 year old man developed jaundice 5 weeks after starting tizanidine [bilirubin peak 4.8 mg/dL, ALT 2387 U/L, Alk P 150 U/L, ANA 1:160] and recovered within 2 months of stopping).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548048</span><span class="label">PMID: <a href="/pubmed/31643379" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643379</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Tipranavir/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Tobramycin/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548048&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548048/?report=reader">PubReader</a></li><li><a href="/books/NBK548048/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548048" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548048" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Tizanidine. [Updated 2017 Jan 30].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548048/pdf/Bookshelf_NBK548048.pdf">PDF version of this page</a> (115K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Tizanidine/AE+AND+Human%5BMH%5D+AND+(drug-induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI+OR+hepatitis,+toxic%5BMH%5D)+AND+(%222009/12/01%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Tizanidine: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Tizanidine" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Tizanidine: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4867418" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4867418" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4867418" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12079683" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Involvement of imidazoline receptors in the centrally acting muscle-relaxant effects of tizanidine.</a><span class="source">[Eur J Pharmacol. 2002]</span><div class="brieflinkpop offscreen_noflow">Involvement of imidazoline receptors in the centrally acting muscle-relaxant effects of tizanidine.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Honda M, Sekiguchi Y, Sato N, Ono H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Eur J Pharmacol. 2002 Jun 12; 445(3):187-93. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643467" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Chlorzoxazone</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Chlorzoxazone<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/6459256" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Tizanidine (DS 103-282) in the treatment of acute paravertebral muscle spasm: a controlled trial comparing tizanidine and diazepam.</a><span class="source">[J Int Med Res. 1981]</span><div class="brieflinkpop offscreen_noflow">Tizanidine (DS 103-282) in the treatment of acute paravertebral muscle spasm: a controlled trial comparing tizanidine and diazepam.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fryda-Kaurimsky Z, Mller-Fassbender H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Int Med Res. 1981; 9(6):501-5. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/7016449" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.</a><span class="source">[Curr Med Res Opin. 1981]</span><div class="brieflinkpop offscreen_noflow">A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Smolenski C, Muff S, Smolenski-Kautz S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Curr Med Res Opin. 1981; 7(6):374-83. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/7970012" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tizanidine: neuropharmacology and mechanism of action.</a><span class="source">[Neurology. 1994]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tizanidine: neuropharmacology and mechanism of action.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Coward DM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Neurology. 1994 Nov; 44(11 Suppl 9):S6-10; discussion S10-1. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643379" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643379" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=604695dc0831bd4666b25475">Tizanidine - LiverTox</a><div class="ralinkpop offscreen_noflow">Tizanidine - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T16:23:40-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal103&amp;ncbi_phid=CE8A79CB0467CBE10000000005230182&amp;ncbi_session=CE8A79CB04695DC1_1315SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548048%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548048&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548048/&amp;ncbi_pagename=Tizanidine - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A79CB04695DC1_1315SID /projects/books/PBooks@9.2 portal103 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>